ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
5.68
-0.15 (-2.57%)
Jul 30, 2026, 10:21 AM EDT - Market open
ARS Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 98.99 | 84.28 | 89.15 | 0.03 | 1.32 | 5.51 | |
Revenue Growth | 1.92% | -5.46% | 297063.33% | -97.72% | -76.10% | - |
Cost of Revenue | 25.62 | 20.42 | 0.98 | - | - | - |
Gross Profit | 73.37 | 63.86 | 88.17 | 0.03 | 1.32 | 5.51 |
Selling, General & Admin | 261.22 | 230.12 | 71.68 | 47.28 | 18.46 | 4.69 |
Research & Development | 14.57 | 13.18 | 19.58 | 20.27 | 18.38 | 20.27 |
Total Operating Expenses | 275.79 | 243.3 | 91.26 | 67.55 | 36.83 | 24.96 |
Operating Income | -202.42 | -179.45 | -3.08 | -67.52 | -35.52 | -19.45 |
Interest Income | - | 10.67 | 11.37 | - | - | - |
Interest Expense | - | -2.6 | - | - | - | - |
Other Non-Operating Income (Expense) | - | - | - | - | -0.14 | - |
Total Non-Operating Income (Expense) | - | 8.07 | 11.37 | - | -0.14 | - |
Pretax Income | -202.42 | -171.38 | 8.29 | -54.37 | -35.66 | -19.45 |
Provision for Income Taxes | - | -0.08 | 0.29 | - | - | - |
Net Income | -197.98 | -171.3 | 8 | -54.37 | -34.68 | -20.24 |
Net Income to Common | -197.98 | -171.3 | 8 | -54.37 | -34.68 | -20.24 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 99 | 99 | 97 | 95 | 40 | 29 |
Shares Outstanding (Diluted) | 99 | 99 | 102 | 95 | 40 | 29 |
Shares Change | -3.81% | -3.74% | 7.54% | 138.30% | 38.39% | 893.01% |
EPS (Basic) | -2.01 | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 |
EPS (Diluted) | -2.01 | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -175.27 | -171.21 | 12.99 | -59.44 | -40.28 | -17.62 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -1.77 | -1.74 | 0.13 | -0.62 | -1.01 | -0.61 |
Gross Margin | 74.12% | 75.77% | 98.90% | 100.00% | 100.00% | 100.00% |
Operating Margin | -204.49% | -212.92% | -3.46% | -225067.00% | -2698.78% | -353.32% |
Profit Margin | -200.00% | -203.25% | 8.97% | -181217.00% | -2635.41% | -367.65% |
FCF Margin | -177.06% | -203.14% | 14.57% | -198137.00% | -3060.56% | -319.94% |
EBITDA | -200.93 | -178.08 | -3 | -67.45 | -35.48 | -19.24 |
EBITDA Margin | -202.99% | -211.30% | -3.37% | -224823.00% | -2696.20% | -349.45% |
EBIT | -202.42 | -179.45 | -3.08 | -67.52 | -35.52 | -19.45 |
EBIT Margin | -204.49% | -212.92% | -3.46% | -225067.00% | -2698.78% | -353.32% |
Effective Tax Rate | - | 0.05% | 3.48% | 0.00% | 0.00% | 0.00% |